Results 231 to 240 of about 389,574 (340)

Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs

The Prostate, EarlyView.
ABSTRACT Background The dog is the only large mammal, other than humans, that commonly develops spontaneous prostate cancer (PCa) and is, therefore, considered a valuable model for comparative studies. Estrogens are critical for normal prostate development and contribute to prostatic carcinogenesis in men.
Jennifer Lothion‐Roy, Leonore Aeschlimann, Lea Anna Hiller, Sven Rottenberg, Nigel P. Mongan, Catrin S. Rutland, Emad Rakha, Alexander Dean, Mark A. Rubin, Simone de Brot   +9 more
wiley   +1 more source

Clinical significance of YAP and androgen receptor expression in osteosarcoma: Evidence from a retrospective cohort study. [PDF]

Medicine (Baltimore)
Wang J, Xiang P, Zou C, Wang J.
europepmc   +1 more source

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

, 2019
E. David Crawford, Bertrand Tombal, Thomas E. Keane, Francesco Boccardo, K. Miller, Neal D. Shore, Judd W. Moul, J.‐E. Damber, Laurence Collette, B.E. Persson   +9 more
openalex   +1 more source

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study

The Prostate, EarlyView.
ABSTRACT Introduction In real‐world practice in Japan, standard treatment for metastatic hormone‐naïve prostate cancer (mHNPC) is androgen deprivation therapy (ADT), administered as monotherapy, combined androgen blockade (CAB), ADT plus androgen receptor pathway inhibitors (ARPIs), or ADT plus docetaxel.
Atsushi Mizokami, Rikiya Matsumoto, Hideaki Miyake, Hiroji Uemura, Hirotsugu Uemura, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Hiroaki Tsuchiya, Sachie Okazaki, Eri Adachi, Ryo Yano, Yohei Tajima, Kiyohide Fujimoto, Hideyasu Matsuyama   +14 more
wiley   +1 more source

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression. [PDF]

J Clin Invest
Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X.   +15 more
europepmc   +1 more source

Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways [PDF]

Yusuf İlhan, Murat Araz, Ali Gürbüz, Semiha Urvay, Muslih Ürün, Berrak Mermit Erçek, Özden Özilice, Onur Yazdan Balçık, Coşkun Yıldız, Hacer Demir, İsmail Beypınar   +10 more
openalex   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Updates in Treatment for Androgenetic Alopecia. [PDF]

Ann Dermatol
Shin JW, Huh CH.
europepmc   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source